Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program




Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program

LAFAYETTE, Colo.–(BUSINESS WIRE)–Building on the progress of the first two rounds, the Center for Disease Analysis Foundation (CDAF) Relink program is pleased to announce seven hundred and eighty-two thousand dollars in funding for its third round of grantees. The following six organizations are beneficiaries:

The CDAF Relink program is in its second year of operation. Funded by an eight-million-dollar grant from the Gilead Sciences (Nasdaq: GILD) Relink program, it is currently the largest global effort to reconnect diagnosed but untreated Hepatitis C (HCV) and Hepatitis B (HBV) infected individuals to care. This is a crucial step toward achieving the World Health Organization’s 2030 Viral Hepatitis Elimination goals in the United States (U.S.). Significant progress has been made toward elimination in the last decade. However, increasing the number of HCV-infected people who complete treatment and are cured, or HBV-infected people who are retained in care remains challenging.

“In the case of HCV, many high-income countries like the U.S. are considered early adopters, that is, they were on the frontlines of diagnosis and treatment for HCV,” noted Homie Razavi, the Managing Director of CDA Foundation. “However, due to fragmented patient management systems, many diagnosed individuals are lost to follow up. It is possible that more than half of the population believed to be diagnosed but untreated may already be receiving care somewhere or have passed away. Additionally, organizational and legal constraints often prevent organizations from fully leveraging patient navigators to engage with the community and link individuals from high-risk groups to appropriate care. However, implementing culturally appropriate and innovative programs which meet patients at their point of need is sure to improve relinkage to care.”

Fundisani Mangena, Chief Operating Officer of First Choice Primary Care, believes the initiative will make a lasting impact on the well-being of the community served by his organization. “This funding supports our mission to improve health outcomes by closing treatment gaps and ensuring patients receive timely, life-changing care,” he stated. “Treatments and medications have come a long way,” said Tuesdae Stainbrook, D.O., MPH, chief investigator of TruReach Inc, another beneficiary. “These funds will help break down barriers that have prevented patients from engaging in care upon diagnosis.”

The call for a fourth and final round of proposals will open in September 2025. Proposals from state health agencies and their partners will be given priority. For more information, please visit https://cdafound.org/relink or contact the CDAF-Relink program at relink@cdafound.org.

About Center for Disease Analysis Foundations

CDA Foundation is a non-profit organization that seeks to help eliminate HBV and HCV globally by 2030 by providing countries across the world with verified epidemiological data, disease burden and economic impact modeling, smart intervention strategies, access to affordable diagnostics and treatments, innovative financing, and knowledge-sharing partnerships to eliminate these deadly infections. It works with more than 110 countries globally and 26 US states on their viral hepatitis elimination programs. CDA Foundation is headquartered in Lafayette.

Contacts

Homie Razavi

hrazavi@cdafound.org

Prollenium Announces Leadership Transition




Prollenium Announces Leadership Transition

Ario Khoshbin transitioning to Prollenium Board role; Walter Geiger Named as Acting CEO

RICHMOND HILL, Ontario–(BUSINESS WIRE)–Prollenium Medical Technologies (“Prollenium” or the “Company”) announced today that Ario Khoshbin is stepping down as Chief Executive Officer to focus on his role as a member of Prollenium’s Board of Directors. Ario remains a significant shareholder of Prollenium.

“Welcoming a CEO with new expertise and perspective will allow Prollenium to continue to achieve its potential as one of the world’s leading global developers and manufacturers of aesthetic products,” said Justin Bateman, Chair of Prollenium’s Board of Directors. “We appreciate and thank Ario for the significant contributions that he has made throughout his long and successful tenure as CEO. We will continue to work alongside the board and leadership team to scale Prollenium’s platform and convert its robust product pipeline into an expanding suite of products to serve both existing and new customers in North America and internationally.”

While the Board conducts a search for a successor, it has appointed Walter Geiger as acting Chief Executive Officer at Prollenium, effective immediately.

A seasoned executive, Walter most recently served as Chairman of the Board for Cellese Regenerative Therapeutics and as President of the Global Consumer Business Unit for Galderma. Prior to Galderma, he served in numerous senior leadership roles at Procter & Gamble, Johnson & Johnson, and Galderma, where he led small and large P&Ls across North America, Asia, and Europe.

“Prollenium’s success has been fueled by its commitment to product development, innovative research, and regulatory and manufacturing excellence,” said Walter Geiger, acting CEO at Prollenium. “I look forward to working with the Board and management team to ensure we continue to execute on its strategic priorities as we begin the next exciting chapter in Prollenium’s story.”

About Prollenium

Prollenium leads the way in facial aesthetics and rejuvenation technology, turning complex science into reliable, effective products. As the first FDA-approved dermal filler manufacturer in North America, Prollenium redefines standards with cutting-edge innovation, exceptional safety, and a portfolio tailored to patient needs.

Contacts

Andrew Merrill/Julia Sidi

Prollenium@prosek.com

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)




Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company’s Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Contacts

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com

Investors:
LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

Media:
LifeSci Communications, LLC

Kendy Guarinoni, Ph.D.

724-910-9389

kguarinoni@lifescicomms.com

Wayde McMillan Elected to Hologic Board of Directors




Wayde McMillan Elected to Hologic Board of Directors

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #governance–Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025.

Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since 2024 after serving as the Chief Financial Officer of 3M Company’s Health Care Business Group since November 2023. Previously, Mr. McMillan served as Executive Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a medical device company, from March 2019 to November 2023. From January 2015 to February 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc, a medical device company. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, a medical device company, Mr. McMillan held a variety of leadership positions at Covidien. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions.

“We’re thrilled to welcome Wayde to Hologic’s Board of Directors,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “His extensive financial expertise and deep understanding of the med-tech industry will be great complements to our current Board.”

Mr. McMillan earned his Bachelor of Science degree in Business Administration from Merrimack College and an MBA from Bentley University’s McCallum Graduate School of Business.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions, and statements regarding the Company’s Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company’s business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

Contacts

Michael Watts
Corporate Vice President, Investor Relations

Michael.Watts@hologic.com
(858) 410-8514

Bridget Perry
Senior Director, Corporate Communications

Bridget.Perry@hologic.com
(508) 263-8654

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System




Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

• Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets

• Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales

RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Lilly a worldwide exclusive license to utilize the STAC-BBB capsid for one initial target, with the right to add up to four additional targets after paying additional licensed target fees, to deliver their intravenously administered genomic medicines to treat certain diseases of the central nervous system.

“We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.”

Under the terms of the agreement, Sangamo is responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products. Sangamo will receive an $18 million upfront license fee from Lilly and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across the five potential neurology disease targets, as well as tiered royalties on potential net sales of such products, subject to certain specified reductions.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter/X.

Forward Looking Statements

This press release contains forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to the potential for Lilly to develop genomic medicines to treat neurodegenerative diseases by leveraging Sangamo’s capsid delivery capabilities, the potential for STAC-BBB to play an important role in the treatment landscape and address challenges in delivering therapeutics to the central nervous system, the potential of Sangamo’s capsids to deliver therapies treating neurological diseases, the potential for Lilly to expand its license to include additional targets and to perform research, preclinical and clinical development, manufacturing and global commercialization of licensed gene therapy products for each licensed target, expectations concerning Sangamo’s receipt of an upfront license fee, the potential for Sangamo to receive additional licensed target fees, milestone payments, and royalties, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research and development process, including the results of preclinical studies and clinical trials; the regulatory approval process for product candidates; the potential for technological developments that obviate technologies used by Sangamo and its partners; the potential discontinuation of industry interest in Sangamo’s capsid delivery technology; any breach or termination of the Lilly agreement; and the potential for Sangamo to fail to realize its expected benefits from the Lilly agreement; Sangamo’s inability to secure additional collaboration partners; and Sangamo’s need for substantial additional funding to operate as a going concern. There can be no assurance that Sangamo will earn any milestone or royalty payments under the Lilly agreement or that Lilly will obtain regulatory approvals for product candidates arising from this agreement. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s and Lilly’s operations and businesses. Sangamo’s risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Contacts

Sangamo Contact
Investor Relations & Media Inquiries

Louise Wilkie

ir@sangamo.com
media@sangamo.com

Scale Bio Joins Chan Zuckerberg Initiative’s Billion Cells Project, Accelerating Single Cell Research at Unprecedented Scale




Scale Bio Joins Chan Zuckerberg Initiative’s Billion Cells Project, Accelerating Single Cell Research at Unprecedented Scale

Scale Bio’s QuantumScale Single Cell RNA Kits Are Now Available for Order to Commercial and Academic Customers, Enabling the Analysis of Millions of Cells in a Single Workflow

SAN DIEGO–(BUSINESS WIRE)–#CZBiohubNY–Scale Biosciences, Inc. (Scale Bio), a leader in highly scalable single cell technologies, today announced its participation in the Chan Zuckerberg Initiative’s (CZI) Billion Cells Project at the Chan Zuckerberg Biohub New York Affiliate Symposium. Scale Bio joins technology partners 10x Genomics and Ultima Genomics in this landmark effort to generate an unprecedented one billion cell dataset to fuel rapid progress in cell biology through AI model development. This collaboration represents a significant expansion of the data generation capabilities for the Billion Cells Project.

Scale Bio is a demonstrated leader in advancing large-scale single cell studies, having leveraged its QuantumScale technology in its “100 Million Cell Challenge,” supported by CZI, Ultima Genomics, NVIDIA, and BioTuring, which helped lay important groundwork for the broader Billion Cells Project. The integration of Scale Bio’s technology with the Billion Cells Project will further accelerate the generation of high-quality, diverse cellular data to fuel advances in biological understanding.

“At Scale Bio, we are focused on accelerating scientific progress through the power of scale to improve human health. For too long, technological limitations have constrained what’s possible in single cell research,” said Giovanna Prout, President and CEO at Scale Bio. “With our QuantumScale and ScalePlex technologies, we’ve reimagined single cell analysis to drive unprecedented scalability, enabling researchers to conduct experiments previously considered infeasible, overly cumbersome, or too expensive. We are proud to collaborate again with CZI and participating researchers on the Billion Cells Project to push the boundaries of single cell omics, helping to generate data across diverse biological models at the scale needed to power new discoveries and develop impactful AI models. We’re excited to see our technologies contribute to such a monumental initiative.”

“Scale Bio will be a valuable partner to help us achieve our grand scientific challenge of building an AI-based virtual cell model to predict and understand cellular behavior,” said Jonah Cool, PhD, Senior Science Program Officer for Cell Science at CZI. “This collaboration will allow researchers to answer specific biological questions about cells and derive high-quality data with unprecedented scale and accessibility. We hope this partnership with Scale Bio is just the beginning of how innovative technologies can remove barriers to data generation, enabling researchers to build more comprehensive AI models that could provide insights into health and disease.”

Scale Bio’s QuantumScale Single Cell RNA kits, which were made available early to 100 Million Cell Challenge winners, are now commercially available in five configurations to academic and commercial customers around the world. The technology is a dramatic improvement over existing solutions, as it can capture and process up to 4 million cells in one short workflow without specialized partitioning instrumentation. Additionally, leveraging ScalePlex technology, researchers can multiplex up to 9,216 samples or conditions per run, making it uniquely suited for large-scale projects.

“With support from CZI and in partnership with interlocking efforts across HuBMAP and the Human Cell Atlas, we’re working to build a comprehensive cellular map of diseases that affect the inhalation interface—from the oral cavity through the upper airway and into the lung,” said Kevin Matthew Byrd, DDS, PhD, Researcher at Virginia Commonwealth University and recipient of a 100 Million Cell Challenge grant. “Chronic conditions like sarcoidosis and Sjögren’s disease impact this entire cul-de-sac of breathing. Scale Bio’s QuantumScale technology allows us to map millions of cells across these connected niches, uncovering shared mechanisms and opening the door to new diagnostic and therapeutic insights.”

Large-scale single cell analysis projects, such as the CZI Billion Cells Project, are critical to building a comprehensive understanding of cellular diversity. These initiatives accelerate understanding of cellular behavior and gene function while fueling the development of AI models that reflect diverse biology. Once completed, this single cell dataset will bring critical new data and resolution to multiple domains of biology that need comprehensive resources, enabling researchers to train AI models and make transformative discoveries across precision medicine and functional genomics.

For more information about the QuantumScale Single Cell RNA kits, visit scale.bio/single cell-rna-sequencing-kit/.

About Scale Bio

Scale Biosciences, Inc. (Scale Bio) is redefining single cell analysis by providing the most scalable omics tools to researchers worldwide, helping to advance the field of single cell omics and to accelerate discoveries in human health and disease. The company’s innovative QuantumScale and ScalePlex technologies enable unprecedented throughput and multiplexing capabilities, allowing researchers to conduct single cell experiments at scales previously unimaginable. For more information, visit scale.bio.

About the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative was founded in 2015 to help solve some of society’s toughest challenges — from eradicating disease and improving education, to addressing the needs of our local communities. Our mission is to build a better future for everyone. For more information, please visit chanzuckerberg.com.

Contacts

Media Contact:


For Scale Bio:

Gwen Gordon

gwen@gwengordonpr.com

We Row For William: 157 Miles, One Nonstop Journey of Hope




We Row For William: 157 Miles, One Nonstop Journey of Hope

Father and Crew to Row 157 Miles Continuously to Fund Lifesaving Gene Therapy for His Son

MEDFORD, Ore.–(BUSINESS WIRE)–On April 25, Joe Jackson and a dedicated crew of men including Jeremy Leever and Shaun Olson will embark on an extraordinary nonstop, overnight rowing journey covering 157 miles of the Rogue River to raise awareness and critical funds for his son, William Jackson, who is battling Duchenne muscular dystrophy (DMD).

What typically takes 10 days, Joe and his crew will complete in a single, grueling push, symbolizing the urgency of finding a cure for this relentless disease. The Rogue River is one of the nation’s most famous whitewater.

Duchenne muscular dystrophy is a progressive, life-limiting genetic disorder that causes muscle degeneration and weakness. To save William and other boys like him, the Jackson family is urgently working to raise $2.2 million to complete development of a CRISPR-based gene therapy. This drug development effort is spearheaded by Cure Rare Disease, a nonprofit biotech pioneering genetic treatment for ultra-rare diseases.

Their first crucial milestone is $800,000 by May 1, a goal they can reach if all 157 miles of this journey are sponsored.

“This is a race against time,” said Joe Jackson. “Rowing 157 miles straight is nothing compared to what William faces every day. We’re doing this to give him and other boys like him a real chance at life.”

How to Get Involved: WeRowForWilliam.org

• Sponsor a Mile: Each mile sponsored brings William closer to his first fundraising goal.
• Donate: Every contribution supports the development of a life-saving gene therapy.
• Spread the Word: Share William’s story and help make an impact.

Every dollar raised will directly fund the development of a first-of-its-kind CRISPR-based gene therapy for William and others fighting Duchenne.

To sponsor a mile, donate, or learn more, visit WeRowForWilliam.org/raiselysite.com or contact Brittany Stineman at Brittany@curerd.org.

About Cure Rare Disease

The mission of Cure Rare Disease is to develop and fund life-saving genetic therapies for ultra-rare diseases, transforming the lives of patients previously deemed untreatable. By fostering strategic collaborations among top researchers, clinicians, policy experts, and donors, Cure Rare Disease brings hope and advances solutions for those awaiting a cure.

Contacts

Media Inquiries:
Brittany Stineman

Brittany@curerd.org
773-751-9010

Mark Farrah Associates Simplifies Analysis of the Medicare Advantage and Prescription Drug Plan Senior Markets




Mark Farrah Associates Simplifies Analysis of the Medicare Advantage and Prescription Drug Plan Senior Markets

MCMURRAY, Pa.–(BUSINESS WIRE)–Mark Farrah Associates’ (MFA), www.markfarrah.com, Medicare Business Online™ (MBO) product simplifies the analysis and tracking of Medicare Advantage (MA) and stand-alone Prescription Drug Plan (PDP) enrollment by health plan as released by the Centers for Medicare & Medicaid Services (CMS). MFA’s improved user interface includes easy-to-navigate tables with download to Excel functionality allowing for swift monitoring of competitive positions in the MA and stand-alone PDP senior markets. Data is organized at national, state, and county levels and is aggregated by parent, contract, and plan. Trend data for Medicare Eligibles and current enrollment for Original Medicare are also featured.

Click here for more information about Medicare Business Online™.

About Mark Farrah Associates (MFA)

MFA is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. Committed to simplifying analysis of health insurance business, our products include: Health Coverage Portal™, Medicare Business Online™, Medicare Benefits Analyzer™, Med Supp Market Data, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus. Follow us on LinkedIn!

Also, for the latest insights about health plan enrollment trends and financial performance, visit the FREE MFA Healthcare Business Strategy Briefs on the MFA website.

Contacts

Mark Farrah Associates

Ann Marie Wolfe, amwolfe@markfarrah.com

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program




BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeiGene–BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to terminate the trial.

“We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “We thank the investigators, their patients, and support staff whose participation and dedication made this research possible.”

Results from this study will be shared at a later date to help advance science and the understanding of anti-TIGIT activity.

About BeiGene

BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of results from the AdvanTIG-302 trial to help advance science and the understanding of anti-TIGIT activity; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To access BeiGene media resources, please visit our News & Media site.

Contacts

Investor Contact
Liza Heapes

+1 857-302-5663

ir@beigene.com

Media Contact
Kyle Blankenship

+1 667-351-5176

media@beigene.com

IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people




IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people

In 1985, IBSA (Institut Biochimique SA) was a small company in Lugano on the brink of bankruptcy. Today, 40 years later, the company celebrates the anniversary of its acquisition by its current CEO and President, Arturo Licenziati, who has led the business with a key philosophy: “Drugs in the best form”.

LUGANO, Switzerland–(BUSINESS WIRE)–#IBSA–The year 2025 marks an important year for the IBSA Group (Institut Biochimique SA), which celebrates a double anniversary: 40 years of leadership by its CEO and President Arturo Licenziati, and 80 years since the creation of the IBSA name. These milestones coincide with another significant event: the 90^th birthday of President Licenziati, who today – April 3, 2025 – celebrates this major occasion.

To mark the company’s 40^th anniversary, IBSA has decided to grant all employees worldwide a day off on August 19, the date when Arturo Licenziati first stepped into IBSA.

“This is just a symbolic gesture to express my gratitude for the commitment, dedication and passion of our People, who are the driving force behind our growth. A growth that is not just about business, but also – and above all – about the ability to implement development and work models that place People at the centre of our philosophy and our activities”, said Licenziati.

Indeed, it was on August 19, 1985, that Licenziati took over the management of the Ticino-based company, founded in Lugano in 1945, redefining its vision and strategy. At that time, IBSA had just 40 employees and a turnover of 5 million Swiss francs. However, by the end of the 1980s – in just 5 years – the company had radically transformed, tripling its revenue.

The history of IBSA is the story of a company that evolved from a small pharmaceutical laboratory in the Swiss Canton Ticino into a multinational corporation. What many people saw as an impossible mission, President Licenziati embraced as a challenge to be won, with the aim of forging a new path, focused on innovation and the ability to respond to people’s actual needs.

“Small companies can only grow if they can adapt quickly to sectors that large pharmaceutical companies often overlook”, added Licenziati. “Over the years, we have transformed an idea –producing “drugs in the best form” – into a concrete and successful project, focusing on targeted research that meets the everyday needs of doctors and patients. We have always been a forward-looking company, ready to go beyond and willing to explore new, uncharted paths”.

Since the 1990s, IBSA has embarked on a global expansion, first in Europe and then worldwide. Today the company has 20 subsidiaries across Europe, China and the United States, and distributes its products in over 90 countries across 5 continents, with more than 2,300 employees between headquarters, subsidiaries and production sites.

Contacts

Chérine Gurtner, Senior Consultant

cherine.gurtner@furrerhugi.ch